Huang P, Gou W L, Wang X T, Ding Y L, He J, Wang C H
Department of Obstetrics and Gynecology, The First Affiliated Hospital of Medical College of Xian Jiaotong University, Xian, Shanxi, China.
Department of Obstetrics, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China.
J Biol Regul Homeost Agents. 2016 Apr-Jun;30(2):523-8.
The purpose of this study is to explore the effectiveness and safety of lactulose oral solution in treating puerperal constipation. The lactulose group was given lactulose, 15 ml once a day, and then given a maintenance dose of 5 ~ 15 ml/time according to defecation condition of patients. Maintenance treatment lasted for one week if the symptoms were relieved; but once symptoms recurred, the medication was restored. Patients in the control group were blank controls. The treatment lasted for six weeks. The conditions of patients, adverse events and combined medication were recorded every day. Patients were evaluated with SF-36 scale before and after treatment. Two hundred and eleven patients with postpartum constipation were selected from five research institutes and they were divided into lactulose group (n=106) and control group (n=105). The curative effect and the improvement of symptoms of the lactulose group were much better than those of the control group (p less than 0.01). Constipation in the lactulose group relieved faster compared to the control group (p less than 0.05). Number of days without constipation in the lactulose group was much more than that of the control group (p less than 0.05). Defecation time in the lactulose group was shorter than that of the control group (p less than 0.05). Dose of lactulose in the lactulose group reduced week by week. Differences of general physical conditions in SF-36 scale between two groups were statistically significant (p less than 0.05). Various vital signs of the two groups had no significant changes after treatment. It can be concluded that, lactulose is an effective and safe drug for treating postpartum constipation.
本研究旨在探讨乳果糖口服溶液治疗产后便秘的有效性和安全性。乳果糖组给予乳果糖，每日1次，每次15 ml，然后根据患者排便情况给予维持剂量5～15 ml/次。若症状缓解，维持治疗持续1周；但一旦症状复发，则恢复用药。对照组患者为空白对照。治疗持续6周。每天记录患者情况、不良事件及联合用药情况。治疗前后采用SF - 36量表对患者进行评估。从5个研究机构选取211例产后便秘患者，分为乳果糖组（n = 106）和对照组（n = 105）。乳果糖组的疗效和症状改善情况明显优于对照组（p＜0.01）。与对照组相比，乳果糖组便秘缓解更快（p＜0.05）。乳果糖组无便秘天数明显多于对照组（p＜0.05）。乳果糖组排便时间短于对照组（p＜0.05）。乳果糖组乳果糖剂量逐周减少。两组在SF - 36量表中的一般身体状况差异有统计学意义（p＜0.05）。两组治疗后各项生命体征均无明显变化。可以得出结论，乳果糖是治疗产后便秘的一种有效且安全的药物。
